scispace - formally typeset
G

Guixue Wang

Researcher at Chongqing University

Publications -  260
Citations -  5693

Guixue Wang is an academic researcher from Chongqing University. The author has contributed to research in topics: Endothelial stem cell & Restenosis. The author has an hindex of 32, co-authored 231 publications receiving 3683 citations. Previous affiliations of Guixue Wang include Xidian University & Chinese Ministry of Education.

Papers
More filters
Journal ArticleDOI

Recent advancements in the use of exosomes as drug delivery systems.

TL;DR: A review of both exosomes derived from various cells and modified exosome and their ability in delivering the many kinds of cargo to the target cell is provided in this paper.
Journal ArticleDOI

Biomimetic Nanotherapies: Red Blood Cell Based Core-Shell Structured Nanocomplexes for Atherosclerosis Management.

TL;DR: This study demonstrates the therapeutic advantages of biomimetic nanotherapy for Atherosclerosis treatment, which holds considerable promise as a new generation of drug delivery system for safe and efficient management of atherosclerosis.
Journal ArticleDOI

Endogenous pH-responsive nanoparticles with programmable size changes for targeted tumor therapy and imaging applications.

TL;DR: P pH-responsive mechanisms for nanocarrier retention at tumor sites, size reduction for penetrating into tumor parenchyma, escaping from endo/lysosomes, and swelling or disassembly for drug release will be highlighted.
Journal ArticleDOI

Biomechanical regulation of vascular smooth muscle cell functions: from in vitro to in vivo understanding

TL;DR: Differential regulation of VSMC functions under two-dimensional conditions in vitro or three-dimensional co-culture conditions in vivo emphasizes the need to construct more actual environments for future research on vascular diseases and cardiovascular tissue engineering.
Journal ArticleDOI

Macrophage membrane functionalized biomimetic nanoparticles for targeted anti-atherosclerosis applications.

TL;DR: It is demonstrated that MM/RAPNPs could efficiently and safely inhibit the progression of AS and may be potential drug delivery systems for safe and effective anti-AS applications.